Clinical-trial-backed calm. No dependency.
NA-Selank (N-Acetyl Selank) is an acetylated form of Selank, a synthetic heptapeptide based on the structure of tuftsin — a naturally occurring immunomodulatory tetrapeptide. It has undergone Phase 1 and Phase 2 clinical trials in Russia with an established safety profile and has been used clinically for anxiety disorders for over a decade.
Unlike traditional anxiolytics, NA-Selank does not cause sedation, cognitive blunting, or dependency — it appears to regulate the anxiety response rather than suppress it broadly.
NA-Selank modulates the GABAergic system — the same system targeted by benzodiazepines — but through a regulatory rather than direct agonist mechanism, which explains the absence of dependency and cognitive side effects. It also influences serotonin and dopamine pathways and has documented enkephalin-stabilizing effects.
BDNF upregulation is a secondary mechanism: unlike most anxiolytics which can reduce BDNF (particularly SSRIs in early stages), NA-Selank increases BDNF — which may account for the simultaneous memory enhancement documented in research.
Phase 1 and Phase 2 clinical trials documented anxiolytic effects with onset and magnitude comparable to low-dose benzodiazepines, without dependency, withdrawal, or cognitive impairment. In direct comparison studies, NA-Selank produced equivalent anxiety reduction to phenibut and diazepam while simultaneously improving cognitive test performance — a result that is impossible with traditional sedating anxiolytics.
Immune modulation has also been documented: NA-Selank influences interferon signaling and T-cell function, which may contribute to resilience under chronic stress.
All information is for educational purposes. These statements have not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease.
Products featuring NA-Selank are launching soon. Browse all formulas →